Response of Oral Citicoline In Primary Angle Closure Glaucoma Measured From Visual Evoked Potential, Contrast Sensitivity, Central Sensitivity, and Mean Visual Field Defect

Lia Meuthia

Purpose: To determine the response of 1 gram oral citicoline towards p100 latency, contrast sensitivity, central sensitivity, and mean visual field defect (MD).

Method: This study was a randomized single-blind clinical trail with crossover method. Subjects consist of 22 Primary Angle Closure Glaucoma (PACG) and were divided into two groups (A and B) with 11 individuals in each group. On phase I, group A received 1 gram oral citicoline daily for four weeks, while grop B received placebo tablet. Wash-out was then carried out for two weeks and subjects were brought into phase II of the trial. During this time, group A received placebo tablet while grop B consumed 1 gram oral citicoline daily. P100 latency, contrast sensitivity, central sensitivity and mean visual field defect examinations were performed at the start of trial, on forth, sixth, and tenth week after the trial had begun.

Result: P100 latency shortening on subjects that received citicoline was significantly greater than the placebo group (p=0.001). Contrast sensitivity was found to be increased (p < 0.001) and MD decreased (p=0.003). The increase of central sensitivity was not significant (p=0.351).

Conclusion: Citicoline in primary angle closure glaucoma for 4 weeks was shown to improve the visual pathway's neurons, proven by P100 latency and contrast sensitivity boost, as well as reduction of MD.